Phase Ib trial of inhaled iloprost for the prevention of lung cancer with predictive and response biomarker assessment

INTRODUCTION: Iloprost, a prostacyclin analog, has lung cancerpreventive activity in preclinical models and improved dysplasia in former smokers in a phase IIb trial. Oral iloprost is currently unavailable. We performed a phase Ib trial of inhaled iloprost in former smokers to assess tolerance and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, York E., Ghosh, Moumita, Merrick, Daniel T., Kubala, Brandi, Szabo, Eva, Bengtson, Lisa, Kocherginsky, Masha, Helenowski, Irene B., Benante, Kelly, Schering, Tia, Kim, Jihye, Kim, Hyunmin, Ha, Duc, Bergan, Raymond C., Khan, Seema A., Keith, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499515/
https://www.ncbi.nlm.nih.gov/pubmed/37711198
http://dx.doi.org/10.3389/fonc.2023.1204726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499515/
https://www.ncbi.nlm.nih.gov/pubmed/37711198
http://dx.doi.org/10.3389/fonc.2023.1204726

Ejemplares similares